• CDC News
  • Adult Immunization
  • Hepatology
  • Rare Disorders
  • Pediatric Immunization
  • Weight Management
  • Screening
  • Psychiatry
  • Allergy
  • Women's Health
  • Cardiology
  • Pediatrics
  • Kidney Disease
  • Dermatology
  • Endocrinology
  • Pain Management
  • Gastroenterology
  • Geriatrics
  • Infectious Disease
  • Orthopedics
  • Obesity Medicine
  • Rheumatology
  • Technology
  • Oncology
  • Nephrology
  • Neurology
  • Pulmonology

Vasomotor Symptoms of Menopause: Enjuvia Now FDA-Approved

Article

The FDA has approved a new syntheticconjugated estrogen formulation(Enjuvia), from Duramed Pharmaceuticals,for the management ofmenopausal vasomotor symptoms.This product is the only plant-derivedsynthetic conjugated estrogen compoundthat includes the componentdelta 8,9-dehydroestrone-an activeestrogenic compound.

Vasomotor Symptomsof MenopauseThe FDA has approved a new syntheticconjugated estrogen formulation(Enjuvia), from Duramed Pharmaceuticals,for the management ofmenopausal vasomotor symptoms.This product is the only plant-derivedsynthetic conjugated estrogen compoundthat includes the componentdelta 8,9-dehydroestrone--an activeestrogenic compound.Clinical studies demonstrate thatthis formulation can reduce the frequencyand severity of hot flashes inmenopausal women. Although dosesas low as 0.3 mg have been reportedto be effective, the FDA has approvedthis product for use in doses of 0.625and 1.25 mg; it is often prescribed inconjunction with a progestin.

Related Videos
Donna H Ryan, MD Obesity Expert Highlights 2021 Research Success and Looks to 2022 and Beyond
Dapagliflozin slows decline of chronic kidney disease
Primary care physicians should prescribe SGLT2 inhibitors
Related Content
© 2025 MJH Life Sciences

All rights reserved.